<DOC>
	<DOCNO>NCT02038673</DOCNO>
	<brief_summary>The objective study determine tolerability , safety , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) , efficacy oral ASP5878 patient solid tumor .</brief_summary>
	<brief_title>An Open-label Phase I Study Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors ( FGFR ) 1,2,3 4 Inhibitor , ASP5878 Single Multiple Doses Patients With Solid Tumors</brief_title>
	<detailed_description>This study consist two part . In dose-escalation part , ASP5878 ( orally available novel small-molecule FGFR 1,2,3 4 inhibitor , multiple dose once-a-day ( q.d . ) , multiple dose twice-a-day ( b.i.d . ) 5-day on/2-day dose twice-a-day ( 5on-2off ) ) administer patient solid tumor increase dose manner , tolerability , safety , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) efficacy ASP5878 evaluate patient . Cycle 0 consist 3 day Cycle 1 subsequent cycle consist 28 day dose-escalation part . In expansion part , 16mg twice-a-day 5-day on/2-day dose ASP5878 ( 5on-2off ) administer patient solid tumor safety , PK , PD efficacy ASP5878 evaluate . The expansion part start Cycle 1 cycle consist 28 day .</detailed_description>
	<criteria>Histologically cytologically confirm solid tumor . Patient must meet least one follow criterion judgment investigator subinvestigator : Disease progression despite standard therapy Progressive disease without standard therapy establish Standard therapy consider intolerable Eastern Cooperative Oncology Group performance status 0 1 . Predicted life expectancy ≥ 12 week judgment investigator subinvestigator . Patient ≥ Grade 2 ( CTCAE v 4.0JCOG ) persistent symptom objective finding due toxicity attributable prior treatment antitumor effect ( except alopecia ) . Patient receive prior treatment intend antitumor effect ( medication , surgery , radiotherapy , etc . ) within 4 week prior plan first day study drug dosing ( patient receive mitomycin C Nitrosourea within 6 week prior plan first day study drug dose ) . A major surgical procedure within 4 week prior plan first day study drug dose surgical procedure plan course study . Patient treat investigational drug medical device within 4 week prior plan first day study drug dose . Patient history organ transplantation . Patient brain metastasis symptom require treatment .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ASP5878</keyword>
	<keyword>FGFR 1,2,3 4 inhibitor</keyword>
</DOC>